Dossier · Private startup · 1 independent source
Latica
Last updated: Jul 31, 2026
Latica is a healthcare real-world-data platform, formerly Lynx.MD, that connects specialty-care providers with life-sciences and medtech users through governed access to structured and unstructured clinical records. Its product combines data ingestion, de-identification, secure workspaces, analytics, and specialty-focused data networks.
Visit WebsiteCompany Overview
Latica is building a medical-intelligence and real-world-data infrastructure business for specialty medicine. The platform is designed to ingest and map heterogeneous records such as physician notes, laboratory results, imaging, video, and other clinical data, then make those assets usable for authorized research and operational workflows. Latica describes two main platform components: a Trusted Data Environment and a Data Exchange. Its stated workflow includes smart ingestion, medical ontology and mapping, automated anonymization of protected health information, natural-language processing, computer vision, governance controls, dashboards, and data-science workspaces. The important product proposition is therefore controlled computation and collaboration around difficult clinical data, rather than a standalone diagnostic model.
The customer model has three sides. Specialty providers contribute or govern the data and can use it for quality improvement, care-gap identification, workflow insight, and data-related revenue opportunities. Life-sciences organizations can use the resulting datasets for real-world evidence, comparative effectiveness, post-market surveillance, cohort discovery, and clinical-development work. Medtech companies are a third target, particularly those needing richer data for product development, validation, or AI-model training. Latica’s current site emphasizes dermatology, gastroenterology, and ENT, while its public network activity highlights specialty-practice partnerships and the value of notes, narratives, images, and longitudinal treatment histories that are often missing from claims-only datasets.
There are credible commercialization signals, but public evidence remains company-reported and does not establish revenue, retention, or profitability. Latica says its network spans more than 400 million patient records and over 100 terabytes of structured and unstructured data; the homepage separately presents 250 million patient encounters, 40 million patients, 29 million notes, and 45 million lab records. These figures should be diligence-checked for overlap, de-duplication, and the distinction between records accessible through the network and records actively used in customer studies. The company has published partnerships or ecosystem activity involving specialty groups including Allied Digestive Health, Schweiger Dermatology, Unio Health Partners, Elevate ENT Partners, Forefront Dermatology, and Florida Digestive Health Specialists. LinkedIn reports 11–50 employees and Palo Alto headquarters with a Tel Aviv location. The company also publicly reports a $12 million seed financing for the former Lynx.MD in 2021; the current capitalization, runway, and any later financing are not established here.
Competition comes from broad healthcare-data networks and evidence platforms such as Datavant, Komodo Health, HealthVerity, Truveta, and Aetion, as well as provider-owned analytics programs, EHR vendors, cloud data platforms, and specialist data-aggregation firms. Latica’s potential edge is the combination of specialty-domain relationships, access to unstructured clinical content, provider-controlled data environments, and packaged research workflows. That edge is only durable if Latica can repeatedly onboard high-quality data, preserve provenance and permissions, demonstrate reproducible study outputs, and turn specialty coverage into a network effect. Larger competitors may have more capital, broader datasets, stronger distribution, or easier access to enterprise procurement.
The defense and national-security case is limited. The core product is commercial healthcare data infrastructure and there is no public evidence reviewed here of defense contracts, military deployments, intelligence use, or security-specific products. The platform could have indirect resilience value for public-health analytics, emergency-care coordination, regulated government health systems, and privacy-preserving research, but those are adjacency scenarios rather than demonstrated markets. Strategic diligence should focus on data-rights durability, privacy and security controls, clinical validity, customer concentration, measurable study outcomes, and whether the company’s software—not merely partner access—is the source of repeatable value.
Strategic Fit Assessment
Latica addresses a real bottleneck in healthcare: making fragmented, unstructured specialty-care data usable without surrendering provider control or patient privacy. Public signals include a live platform, a 2019 operating history, a reported seed round, a current 11-50-person company profile, and continuing specialty-network activity. The internal priority signal is set false because public evidence does not yet establish durable software margins, recurring revenue, retention, current capitalization, or a direct dual-use market; diligence should separate data-network scale claims from contracted and monetized usage.
Strategic Value to U.S.-Israel Alliance
Latica could improve the speed and quality of evidence generation by making provider-controlled clinical data available to authorized researchers, medtech teams, and life-sciences organizations. Its strongest strategic relevance is as privacy-first health-data infrastructure and a possible resilience asset for regulated analytics. That value is materially weaker for a defense-focused thesis because no reviewed source demonstrates military, intelligence, or homeland-security deployment.
Key Technologies
- Structured and unstructured clinical-data ingestion
- Medical ontology mapping and data normalization
- Natural-language processing for clinical notes
- Computer vision for medical images and video
- AI-assisted de-identification of protected health information
- Trusted data environments with granular access controls and audit trails
- Secure analytics workspaces with dashboards and data-science tooling
Use Cases & Applications
- Real-world evidence and comparative-effectiveness studies
- Specialty-care quality improvement and care-gap detection
- Clinical-trial cohort discovery and recruitment support
- Medtech product development, validation, and post-market surveillance
- Life-sciences treatment, outcomes, and market-uptake analysis
- Provider operational analytics across longitudinal patient journeys
- Privacy-preserving AI model development on clinical records
- Public-health and regulated-care analytics where governed data access is required
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 7 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Latica homepage Official product page describing specialty real-world data, reported network metrics, target customers, and platform positioning.
- The Latica Platform Official architecture page describing the Trusted Data Environment, Data Exchange, ingestion, ontology mapping, de-identification, governance, analytics, and workspaces.
- About Latica Official company page stating the 2019 founding, former Lynx.MD identity, ML/NLP approach, investor list, and company-reported data scale.
- Access Data Official customer-facing page describing provider-controlled cloud access, structured and unstructured records, access controls, audit trails, and stated compliance/certification claims.
- Latica LinkedIn company page Company profile identifying Palo Alto headquarters, 11-50 employees, 2019 founding, Tel Aviv location, and current specialty-network activity.
- Lynx.MD is Now Latica Official rebrand announcement identifying Palo Alto and Tel Aviv operations and describing the secure healthcare data-network mission.
- CTech: Lynx MD raises $12 million seed funding Reputable media report of the former Lynx.MD seed financing and named investors; current capitalization is not inferred from it.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.